Twist Bioscience Co. (NASDAQ:TWST) Receives Average Rating of “Moderate Buy” from Brokerages

Twist Bioscience Co. (NASDAQ:TWST) has been assigned a consensus rating of “Moderate Buy” from the eight analysts that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $51.63.

Several research analysts have recently weighed in on TWST shares. TD Cowen boosted their price target on Twist Bioscience from $55.00 to $65.00 and gave the stock a “buy” rating in a research note on Thursday, June 13th. The Goldman Sachs Group lifted their price objective on Twist Bioscience from $45.00 to $55.00 and gave the stock a “buy” rating in a report on Tuesday, July 9th. JPMorgan Chase & Co. boosted their price target on Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a report on Monday, August 5th. Robert W. Baird boosted their price target on Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a report on Monday, August 5th. Finally, Evercore ISI boosted their price target on Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a report on Tuesday.

Insider Transactions at Twist Bioscience

In other Twist Bioscience news, SVP Paula Green sold 1,137 shares of Twist Bioscience stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $39.93, for a total value of $45,400.41. Following the sale, the senior vice president now owns 88,837 shares of the company’s stock, valued at $3,547,261.41. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, CEO Emily M. Leproust sold 13,605 shares of the company’s stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $43.21, for a total transaction of $587,872.05. Following the transaction, the chief executive officer now directly owns 481,918 shares in the company, valued at approximately $20,823,676.78. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Paula Green sold 1,137 shares of the company’s stock in a transaction that occurred on Monday, August 5th. The shares were sold at an average price of $39.93, for a total value of $45,400.41. Following the transaction, the senior vice president now directly owns 88,837 shares in the company, valued at approximately $3,547,261.41. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 42,232 shares of company stock valued at $1,834,749 over the last 90 days. Company insiders own 3.92% of the company’s stock.

Institutional Trading of Twist Bioscience

Institutional investors and hedge funds have recently made changes to their positions in the business. Norges Bank bought a new position in shares of Twist Bioscience in the 4th quarter worth $10,766,000. UBS Group AG grew its stake in Twist Bioscience by 106.4% during the 4th quarter. UBS Group AG now owns 213,467 shares of the company’s stock valued at $7,868,000 after purchasing an additional 110,036 shares during the last quarter. Evoke Wealth LLC purchased a new stake in Twist Bioscience during the 4th quarter valued at about $572,000. Seven Eight Capital LP grew its stake in Twist Bioscience by 154.2% during the 4th quarter. Seven Eight Capital LP now owns 38,420 shares of the company’s stock valued at $1,416,000 after purchasing an additional 23,305 shares during the last quarter. Finally, Virtu Financial LLC purchased a new stake in shares of Twist Bioscience in the fourth quarter worth about $526,000.

Twist Bioscience Stock Up 1.3 %

TWST opened at $43.34 on Monday. The stock has a market cap of $2.54 billion, a PE ratio of -12.90 and a beta of 1.77. The business has a 50 day moving average of $45.23 and a 200-day moving average of $43.56. Twist Bioscience has a 52 week low of $14.42 and a 52 week high of $60.90.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings data on Friday, August 2nd. The company reported ($1.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.71). The company had revenue of $81.50 million for the quarter, compared to analysts’ expectations of $77.40 million. Twist Bioscience had a negative net margin of 74.63% and a negative return on equity of 32.17%. The firm’s quarterly revenue was up 27.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.01) EPS. Equities analysts anticipate that Twist Bioscience will post -3.13 EPS for the current year.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.